Advice

following a full submission:

cariprazine (Reagila®) is accepted for restricted use within NHSScotland.

Indication under review: the treatment of schizophrenia in adult patients.

SMC restriction: for use as a second-line therapy in patients where predominantly negative symptoms have been identified as an important feature.

In patients with stable schizophrenia with predominantly negative symptoms, cariprazine improved negative symptoms more than another second-generation antipsychotic.

Medicine details

Medicine name:
cariprazine (Reagila)
SMC ID:
SMC2137
Indication:
for the treatment of schizophrenia in adult patients.
Pharmaceutical company
Recordati Pharmaceuticals
BNF chapter
Central nervous system
Submission type
Full
Status
Restricted
Date advice published:
13 May 2019